United Therapeutics Corp UTHR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
-
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
-
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
-
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
-
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
-
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
-
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
-
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
Trading Information
- Previous Close Price
- $584.79
- Day Range
- $576.24–590.98
- 52-Week Range
- $409.07–609.35
- Bid/Ask
- $520.00 / $595.00
- Shares Outstanding
- 42.89M
- Market Cap
- $25.20B
- Volume/Avg
- 637,869 / 703,241
Key Statistics
- Price/Earnings (Normalized)
- 19.13
- Price/Sales
- 8.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 10.19%
Company Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,400
- Website
- https://www.unither.com
Valuation
|
Metric
|
UTHR
|
|---|---|
Price/Earnings (Normalized) | 19.13 |
Price/Book Value | 3.90 |
Price/Sales | 8.70 |
Price/Cash Flow | 15.42 |
Price/Earnings
UTHR
Financial Strength
|
Metric
|
UTHR
|
|---|---|
Quick Ratio | 4.89 |
Current Ratio | 5.73 |
Interest Coverage | 118.51 |
Quick Ratio
UTHR
Profitability
|
Metric
|
UTHR
|
|---|---|
Return on Assets (Normalized) | 19.44% |
Return on Equity (Normalized) | 21.74% |
Return on Invested Capital (Normalized) | 19.84% |
Return on Assets
UTHR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|mkJ<RtX | LOCK|kjgkG | $71B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|&d>Gs$B | LOCK|ZmB^ | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|Fd!^!L& | LOCK|#<! | $45B | |||
| Zoetis Inc Class A
ZTS
| LOCK|?>D&#YGW | LOCK|?Y> | $34B | |||
| Viatris Inc
VTRS
| LOCK|DV!k<>% | LOCK|pls | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|<w | LOCK|V^r | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|j#@LZG | LOCK|dVX | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|^V%jWF | LOCK|$C | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|BNL$>$f | LOCK|QZ@f | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|S%JZP?m | LOCK|$l | $2B |
United States